Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Non-cash Items: 2010-2020

Historic Non-cash Items for Myriad Genetics (MYGN) over the last 4 years, with Jun 2020 value amounting to $4.8 million.

  • Myriad Genetics' Non-cash Items was N/A to $4.8 million in Q2 2020 from the same period last year, while for Jun 2020 it was $4.8 million, marking a year-over-year change of. This contributed to the annual value of $4.8 million for FY2020, which is N/A change from last year.
  • Latest data reveals that Myriad Genetics reported Non-cash Items of $4.8 million as of Q2 2020, which was down 0.00% from $4.8 million recorded in Q1 2020.
  • Myriad Genetics' Non-cash Items' 5-year high stood at $8.6 million during Q1 2016, with a 5-year trough of $3.3 million in Q4 2016.
  • Its 3-year average for Non-cash Items is $5.2 million, with a median of $4.8 million in 2019.
  • Per our database at Business Quant, Myriad Genetics' Non-cash Items crashed by 69.44% in 2016 and then skyrocketed by 124.24% in 2017.
  • Quarterly analysis of 5 years shows Myriad Genetics' Non-cash Items stood at $3.3 million in 2016, then soared by 124.24% to $7.4 million in 2017, then decreased by 16.00% to $6.3 million in 2018, then reached $4.9 million in 2019, then reached $4.8 million in 2020.
  • Its last three reported values are $4.8 million in Q2 2020, $4.8 million for Q1 2020, and $4.9 million during Q4 2019.